ABT acquired Androgel in the Sep 2009 buyout of Solvay’s pharma business. The PRGO PR above says Androgel sells $900M annually; however, the US sales, which are what PRGO is chasing, are less than that.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”